Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance

Rhea-AI Summary

Cosmo Pharmaceuticals N.V. (SIX: COPN, FSE: C43) reported robust financial performance for H1 2024, confirming its full-year guidance. Key highlights include:

- Health Tech: $100 million upfront payment from Medtronic, with an additional $100 million expected this year
- Dermatology: Winlevi® continues as the #1 prescribed topical acne product in the U.S.
- Revenue increased to €136.2 million (H1 2023: €43.7 million)
- EBITDA of €94.2 million
- Operating profit of €87.0 million (H1 2023: €7.1 million)
- Net profit of €76.1 million (H1 2023: €1.5 million)

The company confirmed its 2024 guidance with total revenues expected in the range of €260-270 million and operating profit between €159-169 million.

Positive

• Revenue increased significantly to €136.2 million from €43.7 million in H1 2023
• Operating profit rose to €87.0 million from €7.1 million in H1 2023
• Net profit increased to €76.1 million from €1.5 million in H1 2023
• Received $100 million upfront payment from Medtronic with an additional $100 million expected this year
• Winlevi® continues to be the #1 most prescribed topical acne product in the U.S.
• CDMO revenue grew by 9.3% due to increased orders from existing customers
• Strong cash position with €133.4 million in cash and short-term investments at 30 June 2024
• Confirmed 2024 guidance with expected revenue of €260-270 million and operating profit of €159-169 million

Negative

• Net expenses increased to €49.2 million from €36.5 million in H1 2023
• Personnel expenses rose to €19.9 million from €12.2 million in H1 2023
• Outsourced preclinical and clinical trials costs increased to €2.3 million from €1.5 million in H1 2023

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results.

Key highlights

• Health Tech: 
• Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and the delivery of additional AI products/features which will further improve colonoscopy procedure quality measures and efficiency
• The installed base of GI Genius™ continues to grow and ColonPRO™, the new version of GI Genius™ software incorporating an enhanced algorithm resulting in a notable improvement in detection capabilities and additional features to automate the workflow of physicians, was approved by the U.S. FDA in January
• AI Access™ continues to attract external developers; four new applications have been selected for development

• Dermatology: Winlevi^® continues to be the #1 most prescribed topical acne product in the U.S. The global expansion is ongoing, the Canada launch at the end of 2023 is now delivering royalties, and the Australian approval was obtained by Cosmo’s partner Sun in March. The review of the Marketing Authorisation Application by the EMA is ongoing, and submissions for approval have been made in 14 additional countries
• Gastroenterology (GI) product shipments increased to Cosmo’s partners in the reporting period
• CDMO (contract development and manufacturing organisation) continued to grow with revenue increasing by 9.3% due to an increase in orders from existing customers

Pipeline & regulatory highlights

• New GI Genius™ module 300 powered by Nvidia IGX has been submitted to FDA for clearance
• Androgenetic Alopecia phase III trial in males progressing, enrolment near completion for both of the two identical-in-design pivotal trials
• Distal Ulcerative Colitis phase II proof-of-concept study initiated, the 1^st patient is enrolled and the majority of clinical sites are activated
• Bile Acid Diarrhoea phase II proof-of-concept study documents for regulatory submission are under preparation, and the target is to have the study initiated with first patient enrolled by the end of the year
• Solid Tumor phase I study ongoing in patients with advanced refractory solid tumors; the U.S. clinical sites are active, and the enrolment of patients is ongoing
• Lumeblue^® New Drug Application (“NDA”) approved in China; Cosmo’s partner CMS is currently preparing for launch

Half year 2024 financial highlights

• Revenue €136.2 million
• EBITDA of €94.2 million
• Net operating costs €49.2 million
• Operating profit €87.0 million
• Net financial income €1.8 million
• Profit before taxes €88.7 million
• Net cash inflow from operating activities €99.2 million
• Equity attributable to owners of the Company of €498.4 million
• Cash and short-term investments at 30 June 2024 €133.4 million
• A dividend of € 2.00 per share for the financial year 2023 was paid on 12 July 2024

Giovanni Di Napoli, CEO of Cosmo, commented: “We are delighted to report a robust financial performance for the first half of 2024, with revenues reaching €136.2 million, operating profits at €87.0 million, and operating cash flows of €99.2 million. Our flagship products, GI Genius™ and Winlevi®, are driving significant revenue growth, while our pipeline of innovative new products is poised to tap into large, high-potential markets. These outstanding results underscore our commitment to quality, innovation, and enhancing healthcare outcomes for patients worldwide.”

Financial results

EUR 1,000	Half Year
	2024	2023
Revenue	136,237	43,661
Net expenses	(49,283)	(36,538)
Operating profit	86,954	7,123
Net financial income	1,794	(3,450)
Profit before taxes	88,748	3,673
Income tax	(12,690)	(2,187)
Profit after taxes	76,058	1,486
Basic EPS	4.718	0.092
Basic weighted average number of shares	16,105,126	16,146,054
Diluted EPS	4.705	0.092
Diluted weighted average number of shares	16,150,246	16,146,054

 

Revenue in the first half of 2024 increased to €136.2 million compared to €43.7m in the same period last year. Health Tech revenue increased to €97.5 million compared to €6.4 million last year; the increase was driven by the receipt of an upfront payment from Medtronic related to the expansion of the AI partnership. Dermatology revenue increased by 58.5% to €7.4 million due to increases in net sales and the continued global expansion of Winlevi^®. Gastroenterology royalty and supply revenue increased by 4.3% to €21.4 million. CDMO revenue increased by 9.3% to €8.9 million driven by an increase in orders from existing customers.

Net expenses in the first half were €49.2 million compared to €36.5 million in the same period last year. Expenses related to raw materials and consumables increased to €9.2 million compared to €8.6 million in the same period last year as a result of an increase in product shipments in the first half. Personnel expenses increased to €19.9 million compared to €12.2 million last year; the rise in expenses is attributed to an expanded R&D headcount, additional personnel costs related to higher production activity, and higher short-term incentive payments linked to the financial performance Outsourced preclinical and clinical trials costs increased to €2.3 million (H1 2023: €1.5 million) linked to the initiation of the Distal Ulcerative Colitis phase II proof-of-concept study and the costs associated with the preparation for the Bile Acid Diarrhoea phase II proof-of-concept study. Other operating expenses increased by €3.1 million to €10.8 million manly due to an increase in contingent consideration provisions linked to the Company’s new agreement with Medtronic and an increase in production related costs. Depreciation and amortisation increased by €0.4 million to €7.3 million.  

Net financial income was €1.8 million compared to net financial expenses of €3.5 million in H1 2023; the gain relates to interest income on Cosmo’s cash balances and gains on the sale of short-term bond investments. The net financial expenses last year include imputed convertible bonds which were redeemed in the last quarter of 2023 and therefore no change arises in the reporting period.

Profit before tax was €88.7 million (H1 2023: €3.7 million) and profit after tax was €76.1 (H1 2023: €1.5 million).

EUR 1’000	H1 2024	H1 2023
Income statement
Revenue	136,237	43,661
Cost of sales	(23,150)	(18,871)
Gross profit	113,087	24,790
Other income	1,014	425
R&D costs	(10,824)	(8,288)
SG&A costs	(16,323)	(9,804)
Net operating expenses	(26,133)	(17,667)
Operating profit	86,954	7,123
Net financial income/(expenses)	1,794	(3,450)
Profit before taxes	88,748	3,673
Profit after taxes for the period	76,058	1,486
Statement of financial position	30 Jun 2024	31 Dec 2023
Non-current assets	454,658	451,754
Cash and cash equivalents	54,556	50,275
Other current assets	129,038	51,951
Liabilities	132,866	124,944
Equity attributable to owners of the Company	498,443	422,160
Non-controlling interests	6,943	6,876
Equity ratio (%)	79.2%	77.4%
Shares	H1 2024	H1 2023
Weighted average number of shares	16,105,126	16,146,054
Earnings per share (in EUR)	4.718	0.092

 

2024 Guidance

The Company today confirmed its 2024 guidance of:

• Total revenues in the range of € 260 million - € 270 million versus € 92.8 million in 2023
• Operating profit in the range of € 159 million - € 169 million versus € 6.1 million in 2023

Downloads

This media release (https://www.cosmopharma.com/investors/news-and-media) and the full Half Year Report 2024 (https://www.cosmopharma.com/investors/financial-reports) are available on Cosmo’s website.

Half Year 2024 Results Webcast / Conference Call

Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation with Giovanni Di Napoli, CEO, and Niall Donnelly, CFO, to discuss the financial and operating results as well as the next milestones of the Company:

• The webcast presentation will take place today, 24 July 2024, at 2:00 pm CEST
• Participant webcast link: Chrome (recommended) or Firefox:
  https://event.choruscall.com/mediaframe/webcast.html?webcastid=zZeEM8So
  (Please note that there is a function to type in your questions via webcast)
• Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approx. ten minutes prior to the scheduled start of the call:
  Switzerland/Europe:          +41 (0) 58 310 50 00
  United Kingdom:                +44 (0) 207 107 06 13
  United States:                    +1 (1) 631 570 56 13
• The webcast, along with the presentation, will be available as replay online shortly after the event and accessible for three months on https://www.cosmopharma.com/investors/events-and-presentations.

About Cosmo

Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions, and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk®, Lumeblue® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com.

Upcoming Calendar of Events

H.C. Wainwright Global Investment Conference, N.Y.    September 9-11, 2024

UBS Global Healthcare Conference, California              November 11-14, 2024

Contact

Hazel Winchester

Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

hwinchester@cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Attachments

20240724_Cosmo Pharma_Media Release_H1 2024_EN_final

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217556

FAQ

What was Cosmo Pharmaceuticals' revenue for H1 2024?

Cosmo Pharmaceuticals reported revenue of €136.2 million for H1 2024, compared to €43.7 million in H1 2023.

How much was the upfront payment received from Medtronic in H1 2024?

Cosmo received a $100 million upfront payment from Medtronic related to the expansion of their AI-driven partnership in H1 2024.

What is Cosmo's revenue guidance for the full year 2024?

Cosmo confirmed its 2024 guidance with total revenues expected in the range of €260-270 million.

How did Winlevi perform in the U.S. market during H1 2024?

Winlevi continued to be the #1 most prescribed topical acne product in the U.S. during H1 2024.

What was Cosmo's operating profit for H1 2024?

Cosmo reported an operating profit of €87.0 million for H1 2024, compared to €7.1 million in H1 2023.